On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis. Also Read: AbbVie’s Parkinson’s Disease Therapy Hits FDA Roadblock. The immunology portfolio generated $6.97 billion in sales, up 2.3% on a reported basis or 3.5% on an operational basis. Humira revenues were $2.81 billion (down 29.8%), Skyrizi sales reached $2.73 billion (up ...